Connect with us

Market

Trending Penny Stocks For Tuesday October 13: ENTERTAINMENT ARTS (OTCMKTS:EARI), Progressive Care Inc (OTCMKTS:RXMD), Aoxing Pharmaceutical Company Inc (NYSEMKT:AXN)

Published

on

There is one thing that everyone loves: entertainment. Throughout the last couple of decades, it is becoming clear that customers of entertainment do not care whether or not it is digital or traditional. However, what they do prefer is for the entertainment to be more flexible and convenient to them. Because of this, the mixture of technology and entertainment is becoming one of the most popular sectors in the country. In the latest edition of the Global entertainment and media outlook, the worldwide entertainment revenues may grow 5.1% over the next give years, growing from $1.74trn in 2014 to US$2.23trn in 2019. 

ENTERTAINMENT ARTS (OTCMKTS:EARI) is an entertainment company that focus on services that educate, inform, and entertain users. The Company has four companies that “offer services for social media marketing, text marketing campaigns, database design, database management, lead generation programs, design and develop apps, boutique app platform to showcase apps, online educational programs, video games, web content and interactive entertainment.” By using a team of renowned designers, Entertainment Arts Research, Inc provides a unique vision for the future of businesses seeking a global position. The company designs and manufactures a brand that uses the newest technologies and strategies for more revenue.

In August, ENTERTAINMENT ARTS (OTCMKTS:EARI) released an article stating that they would now be providing text-messaging services for clients. GoLoyal is the company offering this; they typically market through email and social campaigns to “attract, retain and expand customer satisfaction.” CEO Joseph Saulter said, “The move to offer text messaging services is another way for our clients to stay informed with their Customers. We are building the infrastructure that will allow us to manage all communication through social media for our Clients. This is vital for all companies as they look to maximize customer relationships.” This has been doing extraordinarily well as EARI has seen lows of $0.04 and has seen a 475% difference including a high of $0.23 over the last 90 days.

Market

Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)

Published

on

By

Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.

REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.

REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.

CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.

Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).

Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.

Continue Reading

Market

ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast

Published

on

By

ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward  to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.

ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.

CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.

MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.

The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.

Continue Reading

Market

Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)

Published

on

By

Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.

CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.

Continue Reading
Advertisement

Trending